Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
出版年份 2017 全文链接
标题
Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
作者
关键词
-
出版物
Scientific Reports
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-03-07
DOI
10.1038/srep42929
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Tumor microenvironment: The culprit for ovarian cancer metastasis?
- (2016) Zhongyue Luo et al. CANCER LETTERS
- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer
- (2016) John R. Webb et al. GYNECOLOGIC ONCOLOGY
- Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application
- (2016) Masaki Mandai et al. International Journal of Clinical Oncology
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Adoptive immunotherapy against ovarian cancer
- (2016) Gloria Mittica et al. Journal of Ovarian Research
- NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
- (2016) Claudia Cantoni et al. Journal of Immunology Research
- Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer
- (2015) Satoru Kitazono et al. Clinical Lung Cancer
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- KEGG as a reference resource for gene and protein annotation
- (2015) Minoru Kanehisa et al. NUCLEIC ACIDS RESEARCH
- Why weight? Modelling sample and observational level variability improves power in RNA-seq analyses
- (2015) Ruijie Liu et al. NUCLEIC ACIDS RESEARCH
- Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome
- (2015) Katharina Auer et al. Oncotarget
- Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer
- (2015) Stefanie Aust et al. PLoS One
- Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype
- (2014) Federico Garrido et al. INTERNATIONAL JOURNAL OF CANCER
- The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
- (2014) Suzanne Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
- (2013) Anna Bachmayr-Heyda et al. BMC CANCER
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
- (2010) Melissa A. Geller et al. CYTOTHERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started